RxDoctor Payments DataLook up a doctor →

Carter Milner, MD

Hematology & Oncology · Jackson, MSNPI 1538322011

Payments from drug & device makers

$261,043in general payments, 2019–2025

Across 626 payments — averaging $417.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$64K
  • E.r. Squibb & Sons, L.L.C.$62K
  • Beigene USA, Inc.$47K
  • Blueprint Medicines Corporation$36K
  • Bristol Myers Squibb$25K
  • Beone Medicines USA, Inc.$11K
  • plus $16K from 54 others
$1,250in research payments, 2019–2025

Across 1 payment — averaging $1250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)68$64,422
E.r. Squibb & Sons, L.L.C.49$61,808
Beigene USA, Inc.38$46,743
Blueprint Medicines Corporation28$35,949
Bristol Myers Squibb71$24,744
Beone Medicines USA, Inc.9$11,040
Johnson & Johnson(2 entities)43$4,176
Amgen17$3,164
GSK4$1,896
Incyte Corporation39$1,326
Novartis33$1,272
Astellas Pharma US Inc20$465
Gilead19$405
Sanofi18$396
Pfizer18$314
Kyowa Kirin, Inc.6$281
AbbVie13$256
Merck12$214
Genentech USA, Inc.9$165
Takeda Pharmaceuticals U.S.A., Inc.10$161
Seagen Inc.6$149
Exelixis Inc.8$148
ADC Therapeutics America, Inc.7$138
Sanofi-aventis U.S. LLC5$104
Taiho Oncology, Inc.3$72
Morphosys, US Inc.4$71
Rigel Pharmaceuticals, Inc.4$70
Karyopharm Therapeutics Inc.4$69
Daiichi Sankyo Inc.3$65
Adaptive Biotechnologies Corporation3$59
Immunocore Limited2$58
Secura Bio, Inc.5$54
Recordati_rare_diseases_inc.3$54
Jazz Pharmaceuticals Inc.3$50
Pharmacyclics LLC, An Abbvie Company3$46
Novo Nordisk2$46
EMD Serono, Inc.3$46
Ipsen Biopharmaceuticals, Inc2$41
Sanofi US Services Inc.2$40
G1 Therapeutics, Inc.2$30
Alnylam Pharmaceuticals Inc.2$29
Verastem, Inc.2$28
Bayer2$28
Regeneron Healthcare Solutions, Inc.2$27
Servier Pharmaceuticals LLC2$26
Teva Pharmaceuticals USA, Inc.2$26
Legend Biotech USA Inc.1$26
Pharmaessentia USA Corporation1$25
Eisai Inc.1$22
AVEO Pharmaceuticals, Inc.1$19
Aurobindo Pharma USA, Inc.1$19
Pharmacosmos Therapeutics Inc.1$18
Dova Pharmaceuticals1$17
Sobi, Inc1$17
Array Biopharma Inc1$17
Azurity Pharmaceuticals, Inc.1$16
Boehringer Ingelheim1$15
Foundation Medicine, Inc.1$13
Tesaro, Inc.1$13
Lilly USA, LLC1$12

How this compares

$261,043 in reported general payments places this provider in the 90th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$131,718
Medicare patients
317
Services billed
1,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →